These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 37330575)

  • 1. Biomarkers as targets for CAR-T/NK cell therapy in AML.
    Shao R; Li Z; Xin H; Jiang S; Zhu Y; Liu J; Huang R; Xu K; Shi X
    Biomark Res; 2023 Jun; 11(1):65. PubMed ID: 37330575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Panorama of Immune Fighters Armored with CARs in Acute Myeloid Leukemia.
    Christodoulou I; Solomou EE
    Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia.
    Sedloev D; Chen Q; Unglaub JM; Schanda N; Hao Y; Besiridou E; Neuber B; Schmitt A; Raffel S; Liu Y; Janssen M; Müller-Tidow C; Schmitt M; Sauer T
    J Hematol Oncol; 2024 Sep; 17(1):85. PubMed ID: 39285441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.
    Miao X; Shuai Y; Han Y; Zhang N; Liu Y; Yao H; Wang X; He G; Chen D; Fan F; Chang AH; Su Y; Yi H
    Front Immunol; 2024; 15():1389227. PubMed ID: 38803489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
    Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
    Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia.
    Mansour AG; Teng KY; Li Z; Zhu Z; Chen H; Tian L; Ali A; Zhang J; Lu T; Ma S; Lin CM; Caligiuri MA; Yu J
    Blood Adv; 2023 Oct; 7(20):6225-6239. PubMed ID: 37379267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.
    Marvin-Peek J; Savani BN; Olalekan OO; Dholaria B
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
    Caruso S; De Angelis B; Del Bufalo F; Ciccone R; Donsante S; Volpe G; Manni S; Guercio M; Pezzella M; Iaffaldano L; Silvestris DA; Sinibaldi M; Di Cecca S; Pitisci A; Velardi E; Merli P; Algeri M; Lodi M; Paganelli V; Serafini M; Riminucci M; Locatelli F; Quintarelli C
    J Hematol Oncol; 2022 Nov; 15(1):163. PubMed ID: 36335396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future.
    Zhang L; Meng Y; Yao H; Zhan R; Chen S; Miao W; Ma S; Xu X; Li Y; Yu M; Han Y; Su W; Han Z; Wang T; Song B; Wang P; Cai H; Yan J
    Am J Cancer Res; 2023; 13(11):5559-5576. PubMed ID: 38058830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research Progress of Chimeric Antigen Receptor Modified NK Cells in the Treatment of Acute Myeloid Leukemia --Review].
    Peng XR; Cheng J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1905-1909. PubMed ID: 38071081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
    Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
    Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TIM3 chimeric antigen receptor-natural killer cells preferentially target primitive acute myeloid leukemia cells with minimal fratricide and exhaustion.
    Klaihmon P; Samart P; Rojanasakul Y; Issaragrisil S; Luanpitpong S
    Exp Hematol Oncol; 2024 Jul; 13(1):67. PubMed ID: 38992654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
    Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
    Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
    Trad R; Warda W; Alcazer V; Neto da Rocha M; Berceanu A; Nicod C; Haderbache R; Roussel X; Desbrosses Y; Daguindau E; Renosi F; Roumier C; Bouquet L; Biichle S; Guiot M; Seffar E; Caillot D; Depil S; Robinet E; Salma Y; Deconinck E; Deschamps M; Ferrand C
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35803613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.
    Limongello R; Marra A; Mancusi A; Bonato S; Hoxha E; Ruggeri L; Hui S; Velardi A; Pierini A
    Front Immunol; 2021; 12():695051. PubMed ID: 34413848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia.
    Gurney M; O'Dwyer M
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.